Literature DB >> 16952972

Rate control in the medical management of atrial fibrillation.

A J Camm1, I Savelieva, G Y H Lip.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16952972      PMCID： PMC1861356          DOI： 10.1136/hrt.2006.099903

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  34 in total

1.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?

Authors:  Aleem U Khand; Andrew C Rankin; William Martin; Jacqueline Taylor; Islay Gemmell; John G F Cleland
Journal:  J Am Coll Cardiol       Date:  2003-12-03       Impact factor: 24.094

3.  Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.

Authors:  Scott D Corley; Andrew E Epstein; John P DiMarco; Michael J Domanski; Nancy Geller; H Leon Greene; Richard A Josephson; Joyce C Kellen; Richard C Klein; Andrew D Krahn; Mary Mickel; L Brent Mitchell; Joy Dalquist Nelson; Yves Rosenberg; Eleanor Schron; Lynn Shemanski; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2004-03-08       Impact factor: 29.690

4.  Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study.

Authors:  Vincent E Hagens; Adelita V Ranchor; Eric Van Sonderen; Hans A Bosker; Otto Kamp; Jan G P Tijssen; J Herre Kingma; Harry J G M Crijns; Isabelle C Van Gelder
Journal:  J Am Coll Cardiol       Date:  2004-01-21       Impact factor: 24.094

5.  Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Authors:  Jonathan S Steinberg; Ara Sadaniantz; Jack Kron; Andrew Krahn; D Marty Denny; James Daubert; W Barton Campbell; Edward Havranek; Katherine Murray; Brian Olshansky; Gearoid O'Neill; Magdi Sami; Stanley Schmidt; Randle Storm; Miguel Zabalgoitia; John Miller; Mary Chandler; Elaine M Nasco; H Leon Greene
Journal:  Circulation       Date:  2004-03-29       Impact factor: 29.690

6.  Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.

Authors:  Jörg Carlsson; Sinisa Miketic; Jürgen Windeler; Alessandro Cuneo; Sebastian Haun; Stefan Micus; Sabine Walter; Ulrich Tebbe
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

Review 7.  Tachycardia-induced cardiomyopathy.

Authors:  Ernesto Umana; C Arturo Solares; Martin A Alpert
Journal:  Am J Med       Date:  2003-01       Impact factor: 4.965

8.  Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial.

Authors: 
Journal:  Am Heart J       Date:  2002-10       Impact factor: 4.749

9.  The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation.

Authors:  Brian Olshansky; Lynda E Rosenfeld; Alberta L Warner; Allen J Solomon; Gearoid O'Neill; Arjun Sharma; Edward Platia; Gregory K Feld; Toshio Akiyama; Michael A Brodsky; H Leon Greene
Journal:  J Am Coll Cardiol       Date:  2004-04-07       Impact factor: 24.094

10.  Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study.

Authors:  Gerian C Grönefeld; Jürgen Lilienthal; Karl Heinz Kuck; Stefan H Hohnloser
Journal:  Eur Heart J       Date:  2003-08       Impact factor: 29.983
View more
  13 in total

1.  Atrial fibrillation: Rate control and digoxin.

Authors:  Gregory Y H Lip; Michael Rudolf
Journal:  BMJ       Date:  2007-12-08

Review 2.  Prospective observational studies of the management and outcomes in patients with atrial fibrillation: A systematic review.

Authors:  Ahmad S Hersi; Alawi A Alsheikh-Ali; Mohammad Zubaid; Jassim Al Suwaidi
Journal:  J Saudi Heart Assoc       Date:  2012-08-23

Review 3.  Atrial fibrillation: mechanisms, therapeutics, and future directions.

Authors:  Jason Pellman; Farah Sheikh
Journal:  Compr Physiol       Date:  2015-04       Impact factor: 9.090

4.  Association between concurrent use of diltiazem and DOACs and risk of bleeding in atrial fibrillation patients.

Authors:  Mohammed Shurrab; Cynthia A Jackevicius; Peter C Austin; Karen Tu; Feng Qiu; Joseph Caswell; Faith Michael; Jason G Andrade; Dennis T Ko
Journal:  J Interv Card Electrophysiol       Date:  2022-09-23       Impact factor: 1.759

5.  Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition.

Authors:  Antonis S Manolis; Theodora A Manolis; Antonis A Manolis; Helen Melita
Journal:  Heart Fail Rev       Date:  2022-03-23       Impact factor: 4.654

6.  New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant.

Authors:  A John Camm; Irina Savelieva
Journal:  J Interv Card Electrophysiol       Date:  2008-06-04       Impact factor: 1.900

7.  Association of Multimorbidity with Cardiovascular Endpoints and Treatment Effectiveness in Patients 75 Years and Older with Atrial Fibrillation.

Authors:  J'Neka S Claxton; Alanna M Chamberlain; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Lindsay G S Bengtson; Alvaro Alonso
Journal:  Am J Med       Date:  2020-04-19       Impact factor: 4.965

Review 8.  Digoxin Use and Adverse Outcomes in Patients With Atrial Fibrillation.

Authors:  Wu-Tao Zeng; Zhi-Hao Liu; Zhu-Yu Li; Ming Zhang; Yun-Jiu Cheng
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.

Authors:  Alon Eisen; Christian T Ruff; Eugene Braunwald; Rose A Hamershock; Basil S Lewis; Christian Hassager; Tze-Fan Chao; Jean Yves Le Heuzey; Michele Mercuri; Howard Rutman; Elliott M Antman; Robert P Giugliano
Journal:  J Am Heart Assoc       Date:  2017-06-30       Impact factor: 5.501

10.  Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study.

Authors:  Maurizio Sessa; Annamaria Mascolo; Mikkel Porsborg Andersen; Giuseppe Rosano; Francesco Rossi; Annalisa Capuano; Christian Torp-Pedersen
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.